Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 461.19
TGTX's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: 461.19 )
TGTX' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 461.19

Equity to Asset 0.94
TGTX's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: 0.94 )
TGTX' s 10-Year Equity to Asset Range
Min: 0.16   Max: 0.97
Current: 0.94

0.16
0.97
F-Score: 4
Z-Score: 54.48
M-Score: -1.94
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -15109.21
TGTX's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: -15109.21 )
TGTX' s 10-Year Operating margin (%) Range
Min: -141552.63   Max: -59
Current: -15109.21

-141552.63
-59
Net-margin (%) -13472.37
TGTX's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: -13472.37 )
TGTX' s 10-Year Net-margin (%) Range
Min: -95121.05   Max: -63.97
Current: -13472.37

-95121.05
-63.97
ROE (%) -51.13
TGTX's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: -51.13 )
TGTX' s 10-Year ROE (%) Range
Min: -1169.76   Max: -8.86
Current: -51.13

-1169.76
-8.86
ROA (%) -42.56
TGTX's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: -42.56 )
TGTX' s 10-Year ROA (%) Range
Min: -1226.5   Max: 3.35
Current: -42.56

-1226.5
3.35
ROC (Joel Greenblatt) (%) -382766.67
TGTX's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: -382766.67 )
TGTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -382766.67   Max: -1066.67
Current: -382766.67

-382766.67
-1066.67
EBITDA Growth (%) -75.20
TGTX's EBITDA Growth (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: -75.20 )
TGTX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 9
Current: -75.2

0
9
» TGTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TGTX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.10
TGTX's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: 6.10 )
TGTX' s 10-Year P/B Range
Min: 0.01   Max: 15.4
Current: 6.1

0.01
15.4
P/S 1666.67
TGTX's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: 1666.67 )
TGTX' s 10-Year P/S Range
Min: 0   Max: 2035.6
Current: 1666.67

0
2035.6
EV-to-EBIT -11.00
TGTX's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: -11.00 )
TGTX' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 5.3
Current: -11

0.1
5.3
Current Ratio 28.30
TGTX's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: 28.30 )
TGTX' s 10-Year Current Ratio Range
Min: 0.06   Max: 35.5
Current: 28.3

0.06
35.5
Quick Ratio 28.30
TGTX's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: 28.30 )
TGTX' s 10-Year Quick Ratio Range
Min: 0.06   Max: 35.5
Current: 28.3

0.06
35.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.60
TGTX's Price/Net Cash is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: 6.60 )
TGTX' s 10-Year Price/Net Cash Range
Min: 1.18   Max: 251.51
Current: 6.6

1.18
251.51
Price/Net Current Asset Value 6.60
TGTX's Price/Net Current Asset Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: 6.60 )
TGTX' s 10-Year Price/Net Current Asset Value Range
Min: 1.18   Max: 251.51
Current: 6.6

1.18
251.51
Price/Tangible Book 6.10
TGTX's Price/Tangible Book is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: 6.10 )
TGTX' s 10-Year Price/Tangible Book Range
Min: 0.65   Max: 5640.85
Current: 6.1

0.65
5640.85
Forward Rate of Return (Yacktman) -1328.54
TGTX's Forward Rate of Return (Yacktman) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. TGTX: -1328.54 )
TGTX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 6.5   Max: 26.9
Current: -1328.54

6.5
26.9

Business Description

Industry: »
Compare: » details
Traded in other countries:NKB2.Germany
TG Therapeutics Inc, a. Delaware corporation was incorporated in 1993 under the name 'Atlantic Pharmaceuticals, Inc.' On April 30, 2012, its name was changed to TG Therapeutics, Inc. It is a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 (ublituximab) which is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The Company is also developing TGR-1202, an orally available PI3K delta inhibitor. The phosphoinositide-3-kinases (PI3Ks) are a family of enzymes involved in cellular functions, including cell proliferation and survival, cell differentiation, intracellular trafficking and immunity. There are four isoforms of PI3K (alpha, beta, delta, and gamma), of which the delta isoform is strongly expressed in cells of hematopoietic origin, and often implicated in B-cell related lymphomas. TGR-1202 is being developed jointly with Rhizen Pharmaceuticals, S A. TGR-1202 has demonstrated activity in preclinical xenograft models and primary cells from patients for hematologic cancers.
» More Articles for TGTX

Headlines

Articles On GuruFocus.com
comment on TGTX Mar 09 2013 
comment on TGTX Mar 09 2013 

More From Other Websites
Nasdaq stocks posting largest percentage increases Jul 21 2014
TG THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material... Jul 21 2014
4:06 pm TG Therapeutics announces preliminary clinical results from its ongoing Phase I study of... Jul 21 2014
TG Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Business Update Jul 21 2014
TG Therapeutics' Novel Combination of TG-1101 (Ublituximab) and TGR-1202 Demonstrates Compelling... Jul 21 2014
TG Therapeutics (TGTX) in Focus: Stock Moves 10.4% Higher Jul 03 2014
UPDATE: MLV & Co. Reiterates On TG Therapeutics On Multiple Positive Factors Jul 02 2014
TG THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 27 2014
Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors Jun 25 2014
TG Therapeutics (TGTX) is Overbought: Is A Drop Coming? Jun 25 2014
TG Therapeutics deal encouraging, says Roth Capital Jun 24 2014
Ligand partnership terms attractive, says Roth Capital Jun 24 2014
TG completes global license agreement with Ligand for IRAK4 Jun 24 2014
TG Therapeutics Completes Global Licensing Agreement With Ligand Pharmaceuticals for the Development... Jun 24 2014
Strength Seen in TG Therapeutics, Inc. (TGTX) as Stock Rallies 12.94% Jun 24 2014
TG Therapeutics, Inc. to Present at the 2014 JMP Securities Healthcare Conference Jun 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide